KR20230079163A - 티아다이아졸론 유도체와 당뇨병 및 관련 장애를 치료하기 위한 ampk 작용제로서 그 용도 - Google Patents

티아다이아졸론 유도체와 당뇨병 및 관련 장애를 치료하기 위한 ampk 작용제로서 그 용도 Download PDF

Info

Publication number
KR20230079163A
KR20230079163A KR1020237014527A KR20237014527A KR20230079163A KR 20230079163 A KR20230079163 A KR 20230079163A KR 1020237014527 A KR1020237014527 A KR 1020237014527A KR 20237014527 A KR20237014527 A KR 20237014527A KR 20230079163 A KR20230079163 A KR 20230079163A
Authority
KR
South Korea
Prior art keywords
compound
pharmaceutically acceptable
formula
present
ampk
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237014527A
Other languages
English (en)
Korean (ko)
Inventor
토마스 에들룬드
제이콥 웨스트만
Original Assignee
베타게논 바이오 에이비
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 베타게논 바이오 에이비 filed Critical 베타게논 바이오 에이비
Publication of KR20230079163A publication Critical patent/KR20230079163A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/08—1,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6536—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and sulfur atoms with or without oxygen atoms, as the only ring hetero atoms
    • C07F9/6539—Five-membered rings
    • C07F9/65392—Five-membered rings containing two nitrogen atoms
    • C07F9/65397—Five-membered rings containing two nitrogen atoms having the two nitrogen atoms in positions 1 and 3

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
KR1020237014527A 2020-10-01 2021-09-30 티아다이아졸론 유도체와 당뇨병 및 관련 장애를 치료하기 위한 ampk 작용제로서 그 용도 Pending KR20230079163A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB2015585.9A GB202015585D0 (en) 2020-10-01 2020-10-01 New compounds
GB2015585.9 2020-10-01
PCT/GB2021/052535 WO2022069894A1 (en) 2020-10-01 2021-09-30 Thiadiazolone derivatives and their use as ampk agonists for the treatment of diabetes and related disorders

Publications (1)

Publication Number Publication Date
KR20230079163A true KR20230079163A (ko) 2023-06-05

Family

ID=73223766

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237014527A Pending KR20230079163A (ko) 2020-10-01 2021-09-30 티아다이아졸론 유도체와 당뇨병 및 관련 장애를 치료하기 위한 ampk 작용제로서 그 용도

Country Status (13)

Country Link
US (1) US20230382930A1 (https=)
EP (1) EP4222147B1 (https=)
JP (1) JP7793614B2 (https=)
KR (1) KR20230079163A (https=)
CN (1) CN116368141B (https=)
AU (1) AU2021352146A1 (https=)
CA (1) CA3193947A1 (https=)
ES (1) ES3018732T3 (https=)
GB (1) GB202015585D0 (https=)
HU (1) HUE071685T2 (https=)
MX (1) MX2023003825A (https=)
PL (1) PL4222147T3 (https=)
WO (1) WO2022069894A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11691954B2 (en) 2019-10-18 2023-07-04 Betagenon Ab Formulations
GB202112529D0 (en) * 2021-09-02 2021-10-20 Betagenon Bio Ab New compounds
EP4600642A1 (en) * 2022-10-05 2025-08-13 Sawai Pharmaceutical Co., Ltd. Method for selecting additive capable of inhibiting nitrosation reaction, and preparation prevented from generation of nitroso compound

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5982281B2 (ja) * 2009-07-08 2016-08-31 バルティック バイオ アーベー 医薬として有用な化合物
WO2013108026A1 (en) * 2012-01-17 2013-07-25 Baltic Bio Ab Thiadiazolone derivatives useful in the treatment of diabetes
AU2018448511B2 (en) * 2018-11-05 2025-07-03 Betagenon Ab Methods of treating diabetes in severe insulin-resistant diabetic subjects

Also Published As

Publication number Publication date
CA3193947A1 (en) 2022-04-07
HUE071685T2 (hu) 2025-09-28
JP7793614B2 (ja) 2026-01-05
CN116368141A (zh) 2023-06-30
ES3018732T3 (en) 2025-05-19
PL4222147T3 (pl) 2025-06-09
EP4222147C0 (en) 2025-03-19
JP2023543924A (ja) 2023-10-18
EP4222147A1 (en) 2023-08-09
AU2021352146A1 (en) 2023-06-01
MX2023003825A (es) 2023-06-06
EP4222147B1 (en) 2025-03-19
GB202015585D0 (en) 2020-11-18
WO2022069894A1 (en) 2022-04-07
US20230382930A1 (en) 2023-11-30
CN116368141B (zh) 2025-09-23

Similar Documents

Publication Publication Date Title
EP4125896B1 (en) Treatment of type 2 diabetes with 2-[(4-{6-[(4-cyano-2-fluorobenzyl)oxy]pyridin-2-yl} piperidin-1-yl)methyl]-1-[(2s)-oxetan-2-ylmethyl]-1h-benzimidazole-6-carboxylic acid or a pharmaceutically salt thereof
KR100967070B1 (ko) 아세트산 아닐리드 유도체를 유효성분으로 하는 과활동방광 치료제
JP7793614B2 (ja) チアジアゾロン誘導体と、それらの糖尿病および関連疾患の治療のためのａｍｐｋアゴニストとしての使用
US20230109134A1 (en) Pyridazinone or pyridazine compound and derivative and pharmaceutical composition thereof
WO2008040192A1 (en) 13,13a-DIHYDROBERBERINE DERIVATIVES, THEIR PHARMACEUTICAL COMPOSITION AND USE
KR20210102887A (ko) 말초 세로토닌과 관련된 질병 또는 장애를 치료하기 위한 트립토판 하이드록실라제 1 (tph1)의 결정질 스피로사이클릭 화합물 억제제
JP2018531288A (ja) ピリミジン組成物、超高純度組成物およびその塩、それを作成する方法、ならびにヒスタミンｈ４受容体（ｈ４）によって媒介される疾患および状態を治療するためにそれを用いる方法
JP2018531288A6 (ja) ピリミジン組成物、超高純度組成物およびその塩、それを作成する方法、ならびにヒスタミンｈ４受容体（ｈ４）によって媒介される疾患および状態を治療するためにそれを用いる方法
JP2022521081A (ja) Ｈｂｖ感染若しくはｈｂｖ誘導性疾患の治療において有用なアミド誘導体
AU2013318672B2 (en) Means and method for treating solid tumours
US20250136563A1 (en) Thiadiazolone derivatives useful as ampk activator
KR20230159375A (ko) 의약에서 사용하기 위한 4-클로로-n-[2-[(4-클로로페닐)메틸]-3-옥소-1,2,4-티아디아졸-5-일]벤즈아미드
JPWO2019031471A1 (ja) 脂肪性肝疾患の治療剤及び肥満症の治療剤
CN109422753A (zh) 一类具有抑制并降解酪氨酸蛋白激酶jak1或jak2活性的化合物
US12522628B2 (en) Aryl glucoside derivative and use thereof in drug
HK40092998A (en) Thiadiazolone derivatives and their use as ampk agonists for the treatment of diabetes and related disorders
HK40092998B (en) Thiadiazolone derivatives and their use as ampk agonists for the treatment of diabetes and related disorders
WO2022189636A1 (en) Anti-inflammatory carboxamide derivatives
CN106432026A (zh) 一类对糖尿病具有潜在治疗活性的化合物
CN109422751A (zh) 一类具有降解酪氨酸蛋白激酶jak3活性的化合物
CN112876352A (zh) 一种gpr120蛋白受体抑制剂及其制备和应用
JPWO2004000841A1 (ja) 二環性複素環化合物
WO2025237355A1 (zh) 一种glp-1受体激动剂化合物、其制备方法及其应用
KR20260032385A (ko) Glp-1 수용체 효능제 활성을 가진 시에노이미다졸 화합물, 이의 제조 방법, 및 이들의 의약 용도
WO2025099561A1 (en) Oral controlled-release matrix formulations of 2-[(4-{6-[(4-cyano-2-fluorobenzyl)oxy]pyridin-2-yl}piperidin-1-yl)methyl]-1-[(2s)-oxetan-2-ylmethyl]-1h-benzimidazole-6-carboxylic acid or a pharmaceutically salt thereof

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

N231 Notification of change of applicant
PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000